Stock Screener App

Gratuito -

Installare

21.00

0.80% -0.17

Alto Neuroscience Inc (ANRO)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Alto Neuroscience Inc Borsa (ANRO) Ultime notizie

Nature Medicine trial: pramipexole eased 'pleasure loss' in depression - Stock Titan

Alto Neuroscience Inc. (ANRO) Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Advances PipelineRevenue Beat Analysis - newsline.com

ANRO Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Investor SentimentEarnings Cycle Outlook - newsline.com

ANRO: Three late-stage psychiatry programs expect pivotal data readouts in 2027 - TradingView

Alto Neuroscience (ANRO) Edges Lower as Stock Hovers Near Key Support ZoneIndex Put Call - The Legal Advocate

Alto Neuroscience (ANRO) director awarded 26,000 stock options at $20.44 strike price - Stock Titan

Alto Neuroscience (ANRO) director Andrew Craig Miller files initial Form 3 - Stock Titan

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller to Board of Directors - geneonline.com

Alto Neuroscience, Inc. (ANRO) Files 8-K Report Announcing No Soliciting Material or Tender Offers – Company Info & NYSE Listing - Minichart

Alto Neuroscience appoints Andrew Miller to board of directors By Investing.com - Investing.com South Africa

Alto Neuroscience appoints Andrew Miller to board of directors - Investing.com

Biotech leader Andrew Miller joins Alto Neuroscience (ANRO) board and governance committee - Stock Titan

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors - Business Wire

H.C. Wainwright reiterates Alto Neuroscience stock rating at buy - Investing.com UK

H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $50 - Moomoo

H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Australia

Wolfe Research initiates Alto Neuroscience stock with outperform rating - Investing.com India

ANRO Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEBITDA Estimate Trend - newsline.com

Alto Neuroscience Analyst Ratings and Price Targets | NYSE:ANRO - Benzinga

BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $33 - Moomoo

BofA Securities Adjusts Price Target on Alto Neuroscience to $33 From $35 - marketscreener.com

Wolfe Research initiates Alto Neuroscience stock with outperform rating By Investing.com - Investing.com Nigeria

symbol__ Stock Quote Price and Forecast - CNN

ANRO Stock Price, Quote & Chart | ALTO NEUROSCIENCE INC (NYSE:ANRO) - ChartMill

Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained - TipRanks

Alto Neuroscience Is Maintained at Outperform by Baird - Moomoo

Alto Neuroscience Price Target Cut to $36.00/Share From $38.00 by Baird - Moomoo

Baird Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $36 - Moomoo

Alto Neuroscience (ANRO) CEO gifts 400,000 shares to family trust - Stock Titan

Alto Neuroscience (ANRO) Vestal Point reports 6.5% ownership - Stock Titan

Point72 affiliates, Steven A. Cohen hold 3.7% of Alto Neuroscience (ANRO) - Stock Titan

[SCHEDULE 13G/A] Alto Neuroscience, Inc. Amended Passive Investment Disclosure - Stock Titan

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Radnet (RDNT) - The Globe and Mail

JonesTrading Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $44 - Moomoo

Mental health scientist wins Columbia Transformational Research Award - Stock Titan

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - Business Wire

Sirenia, Alex Silverstein disclose 7.9% stake in Alto Neuroscience (ANRO) - Stock Titan

Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $35 - Moomoo

Alto Neuroscience (NASDAQ: ANRO) director receives 10,958 stock option grant - Stock Titan

Alto Neuroscience (ANRO) director gets 10,958 options at $24.63 strike - Stock Titan

Alto Neuroscience (ANRO) director receives 10,958-share stock option grant - Stock Titan

Alto Neuroscience (ANRO) director awarded 10,958 stock options as compensation - Stock Titan

York Gwill receives 10,958 Alto Neuroscience (ANRO) stock options grant - Stock Titan

A Quick Look at Today's Ratings for Alto Neuroscience(ANRO.US), With a Forecast Between $24 to $28 - Moomoo

Alto Neuroscience, Inc. Reports Q1 2026 Financial Results and Provides Business Update - Minichart

ANRO: ALTO-207 demonstrates robust efficacy in TRD, with late-stage trials and major catalysts ahead - TradingView

Alto Neuroscience: Runway To Fund Planned Operations Through 2029 >ANRO - Moomoo

Alto Neuroscience Shareholders Shape Governance and Equity Plans - TipRanks

Alto Neuroscience (ANRO) OKs ESPP amendment but rejects equity plan change - Stock Titan

Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $35.52, Implies 44% Upside - TradingView

Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN

ROIV

$30.41

1.27%

MRNA

$55.40

6.27%

BNTX

$89.50

1.43%

RPRX

$54.21

0.11%

ONC

$263.92

1.60%

RVMD

$156.58

2.17%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters